Biosimilars Adoption In Europe, US: Some Wins, 'Incomplete' Policies
Executive Summary
Industry chieftains and experts, including Sandoz biopharma's global head, deliberated at the recent AAM meeting the status of biosimilars adoption in Europe and trends and opportunities to generate savings for both the US federal government and payers.
You may also be interested in...
Biocon-Viatris Biosimilars Combine: Deal Or No Deal?
Are Viatris and long-standing partner Biocon mulling a consolidation of their biosimilars business? Some analysts suggest any deal that positions Viatris as a minority stakeholder in a potential combine doesn’t bode well for the US firm.
Leaders Talk Strategy As India Growth Drives Buoyant Sun
Sun Pharma's senior leadership talks to Scrip about the focus in India on differentiated therapies; the challenges of holding adequate 'strategic inventory' amid waves of the pandemic; and where things stand for active pharmaceutical ingredients. India’s top ranked drug firm is apparently not averse to a role in COVID-19 vaccine distribution, either.
AbbVie’s Stalling Tactics On Humira Pay Off – In More Ways Than One
A US House hearing focused on long-standing criticism of AbbVie for its ability to delay biosimilar competition for Humira. AbbVie was also able to delay the hearing, and that also seemed to work out well for the company.